Oxford Cannabinoid Technologies Holdings non-executive chairman and co-founder Neil Mahapatra joins Proactive London to talk about their progress made after releasing their results for the period ended May 31 2021.
It captures the period that led to its stock market float on May 21, as it raised £16.5mln of new equity to fund the business’s development.
The company has inked agreements with key partners for its lead cannabis drug compound as well as its drug-device/phytocannabinoid combination. It has also acquired key medical assets from Canopy Growth Corporation (TSX:WEED, NYSE:CGC) (TSX:WEED, NYSE:CGC), giving it an exclusive worldwide licence to their entire cannabinoid derivative library, adding 335 derivatives, to more than quadruple in size its prior proprietary library. Timelines for clinical trials have also accelerated as a result of the acquisition.